Abstract:Objective: This study discusses the therapeutic effect of high-dose urokinase treatment for hypertension ventricular hemorrhage. Methods: A total of 60 patients with hypertension ventricular hemorrhage were randomly assigned to two groups: treatment group (n = 30)and control group (n = 30). Both groups received bilateral external ventricular drain. The treatment group was injected with 50,000 IU urokinase to the lateral ventricle every day; the total injection volume per day was 100,000 IU. The control group was injected with 20,000 IU urokinase to the lateral ventricle every day with a total injection volume per day of 40,000 IU. Lumbar puncture was performed in both groups after the later ventricular drain was removed to release cerebrospinal fluid (CSF). Head Computed tomography(CT) examination was performed regularly to observe changes in the ventricular hematoma as well as the occurrence of complications such as intracranial infection and hydrocephalus. Patient prognosis 6 weeks after surgery was compared between the two groups. Results: In the treatment group, the intraventricular hemorrhage clearance time and the number of instances of urokinase treatment were significantly less than those of the control group (P<0.05). The total urokinase dosage of the treatment group was significantly higher than that of the control group (P<0.05). With respect to post-surgery complications, in the treatment group, there were three cases of hydrocephalus and one case of intracranial infection. In the control group, there were four cases of hydrocephalus and three cases of intracranial infection. Intraventricular re-hemorrhage was not observed in either group. Intracranial infection was relieved after strengthened anti-infective therapy and continuous drainage. There was a statistically significant difference in the occurrence of complications between the treatment group and the control group (P<0.05). The rate of good prognosis in the treatment group was higher than that of the control group (P<0.05), and the inefficiency rate was lower (P<0.05). Conclusions: High-dose urokinase treatment produces a significant therapeutic effect in hypertension ventricular hemorrhage. This treatment can quickly eliminate intraventricular hemorrhage, shorten the ventricular drain tube indwelling time, decrease the occurrence of intracranial infection, and increase the likelihood of a good prognosis.

Human urinary kallidinogenase may improve the prognosis of acute stroke patients with early neurological deterioration

The effectiveness and safety of human urinary kallidinogenase in acute ischemic stroke patients undergoing endovascular therapy

Human Urinary Kallidinogenase in Treating Acute Ischemic Stroke Patients: Analyses of Pooled Data from a Randomized Double-Blind Placebo-Controlled Phase IIb and Phase III Clinical Trial

Characteristics and Outcomes of Intravenous Thrombolysis in Mild Ischemic Stroke Patients

Protective effects of human urinary kallidinogenase against corticospinal tract damage in acute ischemic stroke patients

Human urinary kallidinogenase in acute ischemic stroke: A single-arm, multicenter, phase IV study (RESK study)

Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging.

Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.

A Multicenter, Randomized,double-Blinded and Placebo-Controlled Study of Acute Brain Infarction Treated by Humanurinary Kallidinogenase

A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage

Human Urinary Kallidinogenase or Edaravone Combined with Butylphthalide in the Treatment of Acute Ischemic Stroke

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis

Association between baseline hemoglobin level and early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.

Human Urinary Kallidinogenase Promotes Good Recovery in Ischemic Stroke Patients with Level 3 Hypertension.

Corticospinal Tract Hypoperfusion Associated with Unexplained Early Neurological Deterioration after Intravenous Thrombolysis.

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients

Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke.

Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-|[kappa]|B

Efficacy and Safety of Dl-3-n-Butylphthalide Combined With Human Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke

Randomized Controlled Trial of Human Urinary Kallikrein in the Treatment of Acute Cerebral Infarction

Early Neurological Deterioration in Patients with Acute Ischemic Stroke: a Prospective Multicenter Cohort Study